



Faculty of Health Sciences 
Department of Medical Biology 
Medical Pharmacology and Toxicology Research Group 
Modelling of serotonergic receptors and molecular 
optimization of X-ray crystal structures of serotonin 











































This master thesis was written at the Department of Medical Biology at the University of 
Tromsø in collaboration with the Department of Pharmacy (IFA) from August 2015 to May 
2016. 
 
I would like to express my deepest gratitude to the main supervisor Associate Professor Kurt 
Kristiansen and co-supervisor Professor Ingebrigt Sylte for their dedicated assistance, 
guidance and support during the course of this research. With the help of these two fantastic 
supervisors, I have deepened my knowledge and skills in the molecular modelling field. 
I am also immensely thankful to Isak Andreas Bøgwald for teaching me how to use different 
software programs and handle the computational commands and scripts. 
I would also like to extend my deepest gratitude to my parents Goran and Vesna, and my 
brothers Matija and Danilo for encouraging me to study pharmacy and for supporting me 
through all these years. 
 
 




































The serotonin (5-hydroxytryptamine, 5-HT) receptors and transporter are in the serotonergic 
neurotransmission system, and believed to have a major role in pathology of depression. They 
are of pharmacological importance, being targeted by many nowadays antidepressants. It is 
therefore of great interest to understand their structural and functional properties for 
development of future drugs.  
There is generally little knowledge today about the effects of environmental toxicants on the 
human brain. If the exogenous compounds interact with the serotonin receptors and 
transporter, they may interfere with the serotonergic neurotransmission in the brain and 
interfere with the effects of the CNS drugs. 
 
Homology modelling is an in silico method used for prediction of the 3D structure of 
structurally unknown proteins. Models of serotonergic receptors (5-HT1A, 5-HT2A, 5-HT2C) 
were constructed by the homology approach with known structures in the PDB. The newly 
released X-ray crystal structures of the human serotonin transporter (SERT) were also 
imported from the PDB and optimized with molecular modelling techniques. Molecular 
docking was utilized to predict putative harmful effects and drug interactions of the toxicants 
in the Tox21 database with these protein targets. Many toxic compounds were predicted to 
interact with serotonergic receptors and the SERT and many of these had physiochemical 
properties that suggest that they may act in the CNS. Detailed interaction analysis of the 
selected compounds of serotonergic receptors and the SERT indicated that besides the crucial 
interaction with an aspartic acid, aromatic interactions with phenylalanine residues are also 
very important. The obtained high CNS MPO scores and similar Glide scores between the 
known high affinity binders and toxicants could suggest harmful effects and drug interactions 
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1.1 Environmental toxicants and their effects on the central nervous system 
(CNS) 
 
Environmental toxicants include organic and inorganic substances that are harmful to human 
health and development. To which degree individuals are exposed to these chemicals is 
depended on factors as lifestyle, living and working place, foods and drinks, pharmaceutical 
consumption and radiation. The most commonly studied environmental toxicants are heavy 
metals, air pollutants and pesticides (1).  
Environmental toxicants are seen as a major public health issue, though little is known about 
their effects on the human brain. Still, there is convincing evidence that chemicals in the 
environment can alter functions of the nervous system (2).  
Dementia and Parkinson’s syndrome have been associated with aluminium toxicity, while 
cerebellar ataxia with dementia have been associated with lithium overdose, and severe 
psychotic disorders with lysergic acid diethylamide (LSD). However, putative psychiatric and 
psychological problems associated with exposure of environmental chemicals are not much 
studied and even trivialised and more research is needed into both the acute and chronic 
effects of neurotoxic exposure on mental functions (3). 
To get insight into if and how environmental toxicants may affect mechanisms in the human 
body, we need to understand their molecular interactions with human proteins including 
receptors involved in cellular signalling. Environmental toxicants may interact with human 
receptors and transporters and thereby affect the actions of neurotransmitters, hormones and 
inflammatorial mediators. They may also resemble the interactions of drugs with their targets 
and thereby interfere with pharmacological effects of drugs.  
Sedation may be a form of neurotoxicity and it was suggested that one of the reasons for 
sedation is caused by interaction of toxicants with cell membranes in the CNS (either directly 
with membrane lipids or with membrane proteins), which impairs their electrical and 
chemical cell signalling (4). All toxicants that are able to cross the blood brain barrier (BBB) 
could possibly interact with receptors and transporters in the CNS and thereby give 
physiological effects. 
In 2008, the National Institutes of Health (NIH) and the U.S. Environmental Protection 
Agency (EPA) announced a new toxicity testing initiative called Toxicology in the 21st 
Century (Tox21). This collaboration has contributed to the establishment of a database named 
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Tox21 library, which is now a collection of approximately 10 000 unique environmental 
chemicals and approved drugs. Tox21 researchers aim to develop better toxicity assessment 
methods to quickly and efficiently test whether certain chemical compounds have the 
potential to disrupt processes in the human body that may lead to negative health effects (5). 
 
 
1.2 Blood-brain barrier 
 
Not all the chemicals can reach and affect the CNS. They are prevented by the blood-brain 
barrier (BBB) and endothelial cell-astrocyte interactions.  
The BBB consists of unusual tight junctions formed by endothelial cells surrounding 
capillaries that supply the brain tissue. This barrier prevents the free passage of the most 
blood-borne substances and thus maintains the control of what is entering the brain.  
Some chemicals can, however, cross this barrier and enter the CNS. Compounds may either 
use special transport mechanisms or they could cross the membrane by passive diffusion if 
they are lipid soluble. The required nutrients, amino acids, fatty acids, hormones etc., are 
reaching the brain by these mechanisms. So, the environmental toxicants that structurally 
resemble these substances, or are lipid-soluble, may enter the CNS (2). 
It is important to mention, that the BBB’s permeability for chemicals is age-related and the 
BBB is not complete for until about 6 months after birth. The human brain continues to 
develop in the postnatal period, and is highly vulnerable over many months, through infancy 
and into early childhood (6,7). This means that some chemicals that are not harmful to adults, 
may be susceptible to injury children’s brain, and other substances that are harmful in the 
mature brain at certain doses, may need even smaller doses to give neurotoxicity in children. 
 
 
1.3 G-protein coupled receptors 
 
At least 30% of all drugs on the market are targeting G-protein coupled receptors (GPCRs). 
GPCRs is the largest superfamily of membrane-bound receptors numbering around 800 
members in the human genome (8). They are divided into several families (A-F), where A, B 
and C are the three main families.  
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All GPCRs share a common architecture of seven-transmembrane (7TM) α-helices. They are 
cell surface receptors (located in the lipid bilayer) that mediate biological responses to 
external stimuli by transducing signals across the plasma membrane to heterotrimeric  
G-proteins and arrestins, which in turn activate cellular signalling cascades. Their signal 
transduction is fundamental for most physiological processes and these receptors mediate the 
actions of neurotransmitters, hormones and paracrines. This makes them important 
therapeutic targets for drugs acting at receptors as agonists or antagonists (8,9). 
Different experiments have shown that GPCRs can undergo conformational changes between 
active and inactive conformations (10). The binding of antagonists or inverse agonists 
stabilizes an inactive conformational state of the receptor, while the binding of agonists 
stabilizes an active conformational state of the receptor. 
GPCRs interact with heterotrimeric G-proteins located in the intracellular part of a cell, made 
up of a Gα-subunit and a Gβγ heterodimer. When an agonist binds to a GPCR, the GPCR 
changes its conformation from an inactive to an active conformational state. Following this, 
the GPCR interacts with the appropriate G-proteins. This causes changes in the conformation 
of the Gα-subunit and the release of guanosine diphosphate (GDP).  
Guanosine-5’-triphosphate (GTP) binds to the ternary complex consisting of the agonist, the 
GPCR and the G-protein. Subsequently, conformation of Gα-subunit changes and the 
heterotrimeric G-protein-complex dissociates into a Gα-GTP and a Gβγ-complex. The Gα-
GTP and a Gβγ-complex stimulate and inhibit specific effector proteins (enzymes and ion 
channels) leading to cellular effects (Fig. 1) (11). 
 
Fig. 1. The figure illustrates the function of the GPCRs (12). 
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1.3.1 Family A of G-protein coupled receptors 
 
Family A of GPCRs makes up the vast majority of the GPCRs. They consist of a 7TM helical 
bundle in the membrane, three extracellular and three intracellular loops (ECLs and ICLs) 
connecting the individual helices and an extracellular N-terminus and an intracellular 
C-terminus. Typical for most of the family A GPCRs is a disulfide bridge between the ECL2 
and the upper part of TM helix III. Most family A receptors also have a palmitoylated 
cysteine in the C-terminus (Fig. 2) (13). 
 
 
Fig. 2. Structure of the β2-adrenergic receptor (family A of GPCRs) with a bound inverse agonist carazolol  
(PDB ID: 2RH1), Cherezov et al. (8); I-VII TM helices; VIII helix; 1-3 ICL – intracellular loops; 1-3 ECL – 
extracellular loops. The TM helices are marked with Roman numerals I-VII. The backbone atoms of the receptor 
are shown. 
 
Different experimental approaches have shown that TM helix III plays a decisive role in 
ligand binding and receptor activation (8). Additionally, X-ray structures complexes have 
shown that ligands are making contact with residues in helices III, VI and VII, which define 
the orthosteric binding pocket, and in some cases with helix V, which is an important 




1.4 Serotonin as a neurotransmitter and its receptors 
 
Serotonin, also known as 5-hydroxytryptamine (5-HT), is a major neurotransmitter found in 
the CNS and many peripheral tissues (14). It regulates several functions such as dopamine 
release, cognitive function, learning, memory, appetite, immune function, arousal, sexual 
desire, vascular tone, and coagulation (15). Serotonin plays an important role in controlling 
behaviour and mental status and has been implicated in the pathogenesis of many psychiatric 
disorders, including depression and anxiety (16). 
The biosynthesis of serotonin takes place in the presynaptic serotonergic neurons of the CNS, 
where it is synthesized from the essential amino acid tryptophan (Trp). Tryptophan is 
converted to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase and then to serotonin 
by aromatic amino acid decarboxylase (Fig. 3) (17). 
The effects of serotonin are mediated by serotonin receptors. During the past two decades, 
multiple 5-HT receptors subtypes have been characterized (5-HT1-7), based on their amino 
acid sequence homology, ligand affinity and signalling pathways. All the serotonin receptors 
belong to family A of GPCRs, with one exception the 5-HT3 receptor, which is a ligand-gated 
ion channel receptor (8,14). 
In 2013, the crystal structures of the 5-HT1B and the 5-HT2B receptor in complex with two full 
agonists ergotamine (ERG) and dihydroergotamine (DHE), respectively, were reported by 
Wang et al (18). These receptor structures represent an agonist bound state of the 5-HT1B 
receptor and an arrestin biased state (the receptor conformation for interactions with arrestin) 
of the 5-HT2B receptor. This has enabled construction of homology models of other 
serotoninergic GPCRs. Molecular docking of 5-HT into the orthosteric binding pocket of the 




Fig. 3. A simplified illustration of the serotonergic system. Trp, tryptophan; TH, tryptophan hydroxylase;  
5-HTP, 5-hydroxytryptophan; AADC, aromatic amino acid decarboxylase; 5-HT, 5-hydroxytryptamine; SERT, 




1.4.1 Serotonin receptors 5-HT1A and 5-HT2A/2C 
 
The 5-HT1A receptor inhibits adenylyl cyclase, increases the potassium conductance by 
regulating inward rectifying potassium channels, and decreases the opening of voltage gated 
calcium channels, and mainly function as an inhibitory presynaptic and postsynaptic receptor. 
The receptor has an important role in depression (19). When activated by serotonin, the  
5-HT1A receptor triggers the opening of potassium channels in the cell membrane and 
hyperpolarisation of the cell, which further results in a reduction in the discharge rate.  
The 5-HT2 receptor subfamily preferentially couples to Gq/11 to increase inositol phosphates 
and cystolic [Ca2+].  
The 5-HT2A receptor is an important member of this family and this subtype of 5HT2 
receptors is widely distributed at varying densities throughout the brain. As for the  
5-HT1A, there are cumulative evidences indicating a role in depression (19). Many 
antidepressants and antipsychotic agents bind with high affinity to this receptor. Blockade of 
5-HT2A receptor might enhance the 5-HT1A receptor-mediated neurotransmission in cortical 
and limbic areas. This effect is likely to be linked to the efficacy of antidepressants. 
The 5-HT2C receptor is predominantly located in the choroids plexus, cerebral cortex, 
hippocampus, substantia nigra and cerebellum. The 5-HT2C receptor also plays a role in 
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depression and is involved in the actions of several antidepressant drugs. An altered editing of 
the mRNA encoding this receptor has been reported in the prefrontal cortex of depressed 
suicide victims, suggesting an abnormal function of the receptor protein. Preclinical studies 
have shown that selective and nonselective 5-HT2C antagonists potentiate the neurochemical 
effects of SSRIs on hippocampal and cortical extracellular serotonin levels (19). 
 
 
1.4.2 Serotonin transporter (SERT) 
 
The serotonin transporter (SERT) belongs to the neurotransmitter sodium symporter (NSS) 
family and is one of the most widely studied NSS transporters. The SERT plays a key role in  
serotonergic signalling by removing 5-HT from the synaptic cleft into the presynaptic neuron. 
In presynaptic neurons, serotonin is either recycled into storage vesicles or converted to the 
inactive metabolite 5-hydroxyindolacetic acid (5-HIAA) by the monoamine oxidase (MAO) 
(Fig. 3) (17,20). The SERT can be inhibited by drugs, such as antidepressants, hence 
enhancing the serotonergic neurotransmission (21,22). This makes SERT an important 
pharmacological target. 
X-ray crystal structures of the human SERT in complex with two antidepressants:  
(S)-citalopram and paroxetine, were recently reported by Coleman et al (23). 
Both an allosteric and an orthosteric binding site were identified in the X-ray crystal 
structures. These SERT structures define the mechanism of antidepressant action and give 
hopes for future drug design, and must be regarded as an important breakthrough in the search 
for new antidepressant drugs.  
Until 2013, only one member of NSS transporters was solved by X-ray crystallography, the 
prokaryotic Aquifex aeolicus leucine transporter (LeuT). This is why homology modelling 
has been an important technique to study NSS transporters. Gabrielsen et al used the LeuT 
structure as template for constructing SERT homology models. The project’s purpose was the 
identification of novel SERT compounds and several high affinity binders were identified by 






Fig. 4. Structure of human SERT imported from the PDB (PDB ID: 5I71) and protein prepared in Maestro. The 




1.5 Future aspects in pharmacological treatment of depression and anxiety 
 
Clinical depression or major depressive disorder (MDD) is the most common psychiatric 
disorder worldwide. It is a medical condition that may cause serious, long-lasting symptoms 
and often disrupts a person’s ability to perform routine tasks. It can take different forms and 
has varying levels of severity. People with untreated depression have lower quality of life and 
an increased risk for suicide (24). 
It is reported 5-600 suicides every year in Norway, because of major psychiatric disorders. 
The society pays up to $8.5 billion (70 billion Norwegian Krone) annually, mostly on 
treatment of depression and anxiety (25).  
 
The main theory of depression is the monoamine hypothesis proposed by Schildkraut in 1965 
(26). It states that depression is caused by a functional deficit of the monoamine transmitters, 
noradrenaline and serotonin at certain sites in the brain, while mania results from the 




Table 1. Pharmacological evidence supporting the monoamine hypothesis of depression (12). 
Drugs Principal action Effect in depressed patients 
Tricyclic antidepressants 
(TCA) 
Block noradrenaline and 
5-HT reuptake 
Mood ↑ 
Monoamine oxidase (MAO) 
inhibitors 
Increase stores of 
noradrenaline and 5-HT 
Mood ↑ 
Selective serotonin reuptake 
inhibitors (SSRI) 
Block 5-HT reuptake Mood ↑ 
Reserpine Inhibits noradrenaline and 
5-HT storage 
Mood ↓ 
Methyldopa Inhibits noradrenaline 
synthesis 
Mood ↓ 
α-Methyltyrosine Inhibits noradrenaline 
synthesis 
Mood ↓ 
Tryptophan depletion Decreases brain 5-HT 
synthesis 
Induces relapse in 
SSRI-treated patients 
Tryptophan Increases 5-HT synthesis Mood ↑ (in some studies) 
 
An important question is if environmental toxicants can contribute to the impairments of 
neurotransmission by interacting with serotonergic receptors and transporters, and thereby 
possibly could modulate the actions of antidepressant drugs. 
 
Perhaps the strongest evidence for the role of the serotonergic system in MDD is the efficacy 
of antidepressants that target the SERT. These are the selective serotonin reuptake inhibitors 
(SSRIs) and the dual serotonin and norepinephrine reuptake inhibitors (SNRIs). The two 
mentioned groups of antidepressants account for more than 90% of the global antidepressant 
market (19). 
SSRIs show selectivity with respect to serotonin over noradrenaline reuptake. They are less 
likely to cause anticholinergic side effects and are less dangerous than tricyclic 
antidepressants (TCAs) (12). 
However, the antidepressant effect is not seen immediately. Beneficial effects from the 
treatment appear within one or two weeks, while the full effect may be seen after 6 to 12 
weeks. It is important to mention that the direct neurochemical effects of antidepressant drugs 
appear very rapidly (within minutes to hours), while the adaptive changes in the brain 
responsible for the clinical improvements, take much longer time to obtain (12,24). 
The antidepressant market is believed to be almost saturated with antidepressants, and new 
drugs can only achieve success if they prove to be faster acting and/or more efficacious than 
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SSRIs and SNRIs. Future development can rely on knowledge of the role played by the 
different 5-HT receptors in depression.  
The presynaptic 5-HT1A receptor is suspected to play an important detrimental role in the 
slow onset of action due to activation of negative feedback mechanisms taking place in 5-HT 
neurons. On contrary, activation of postsynaptic 5-HT1A receptor in corticolimbic networks 
has positive antidepressant action. It is also shown that blockade of 5-HT2A and 5-HT2C 
improves the action of SSRIs.  
One of the strategies in the development of new antidepressants drugs might include 
combinations of SERT blockade and agonising/antagonizing activities at most relevant 
serotonergic receptors. Vilazodone, a drug approved in 2011 in the United States, is 






Antidepressants are not the only method in treatment of the MDD. The first line of treatment 
of depression in Norway is non-medicament psychotherapy, assisted programmes for physical 
activity and advices on how to solve the problems on daily basis. Antidepressants are 
considered as an option only if psychotherapy attempt is not sufficient (27). 
There are many different forms of psychotherapy, and a variety of techniques are used to treat 
their patients, depending on their life situation and degree of depression. 
Options for treatments include: cognitive-behavioural therapy, problem solving therapy, 
supportive psychotherapy, psychodynamic psychotherapy, family and couples therapy.  
Psychotherapy is generally not used alone for patients with severe depression. Major 
depression can be treated with antidepressants or psychotherapy, or a combination of both. 








1.6 Computational science and drug discovery 
 
In drug discovery, computational methods have been playing a major role in the development 
of therapeutically important molecules for several years. Computer based methods allow rapid 
screening of large compound libraries and determination of potential binders through 
modelling, simulation and visualization techniques. These computational methods are 
classified either as structure-based or ligand-based. Ligand based methods take into account 
only ligand information, and predict activity based on its similarity or dissimilarity to 
previous known active ligands. On contrary, in structure-based methods both the structure of 
the target and of ligands binding to the target are known. Structure-based computer-aided 
drug design (SB-CADD) relies on the ability to determine and analyse 3D structures of 
biologic molecules. This approach predicts the ability of a molecule to favourably interact 
with a particular binding site on a specific protein.  
In this project SB-CADD method will be applied through molecular modelling, including 
homology modelling and docking and scoring to examine if putative toxic compounds 
interact with serotonergic receptors and the SERT. 
Software and databases are also a part of computational science. Structural information about 
the target protein is necessary for SBB-CADD approach. The Protein Data Bank (PDB) 




1.6.1 Molecular modelling 
 
Molecular modelling is a collection of computer based techniques for deriving, representing 
and manipulating the structures and reactions of molecules, and properties that are dependent 
on 3D structures. It generally accounts two computational approaches, molecular mechanics 
(MM) and quantum mechanics (QM) (29). 
The molecular mechanics consider the atomic composition of a molecule to be a group of 
masses interacting with each other via harmonic forces. The method enables the calculation of 
the total steric energy (Etot) of a molecule in terms of deviations from reference unstrained 
bond lengths (Ebond), angles and torsions (Eangle, Etors), plus non-bonded interactions (Evdw, 
Eelec), as shown in the following equation: 
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Etot = Ebonded + Enon-bonded; or 
Etot = (Ebond + Eangle + Etors) + (Evdw + Eelec) 
 
The QM approaches are very valuable tools in computational chemistry. Properties like 
molecular geometry and relative conformational energies can be calculated with high 
accuracy for a broad variety of structures. However, QM is disadvantageous relative to other 
methods because of the computational costs and the limitation to rather small molecules. 
Unlike the MM, QM is not applicable to large biological molecules such as proteins, DNA 
and lipid membranes (30). 
 
 
1.6.2 Homology modelling 
 
Homology modelling, also called comparative modelling is an in silico method used to 
predict the 3D structure of a query amino acid sequence based on a homologous 
experimentally determined structure (the template) (31). 
This approach aims to establish the relationship between residues of the target and those of 
the template. For protein receptor models, the correspondence of binding pocket residues is of 
special concern. 
Proteins that have evolved from a common ancestor are said to be homologous. Two 
homologous sequences can be nearly identical, similar to varying degrees or dissimilar 
because of extensive mutations. When a sequence with unknown protein 3D structure is 
found homologous to another protein sequence, and there is a 3D structure available for that 
sequence, the homology modelling approach is the method of choice for predicting the 3D 
structure of the protein sequence of unknown 3D structure. The prediction is based upon 
amino acid sequence alignments between the target and the template (30). 
The first step in homology modelling is to determine which protein structures that can be used 
as templates. Templates for homology modelling can be found in the PDB. These are 
structures solved by X-ray crystallography or NMR. When choosing a template of known 3D 
structure, it is important to consider its crystallographic resolution if it is an X-ray structure 
(the R-factor). A lower R-factor indicates more detailed structural information which will 
give a more accurate 3D model. Structures with R-factor resolution of 2.0 Å or lower are 
considered to be reliable. Structure comparison of putative templates is also necessary in the 
process of template selection and alignment correction. The template has to be closely related 
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to the modelling target, having significant similar structural and functional properties. The 
sequence identity of the template and the target should be high, especially in the binding 
pocket, as it will provide a more reliable model conformation. If the template chosen is 
crystallized with a ligand, the target model will also be in a more appropriate state for ligand 
docking (30).  
	
	
Fig. 5. Steps in homology modelling (31). 
 
The second step in homology modelling is mapping of corresponding residues between the 
target sequence and template structure, the process often referred to as sequence–structure 
alignment. The sequence–structure alignment aims to reproduce this correspondence as 
accurately as possible, but without the benefit of knowing the “real” (experimental) structure 
of the modelling target. An accurate sequence–structure alignment should include all the 
structurally and evolutionary equivalent residue pairs, at the same time leaving out 
structurally different regions (31). 
The third step in homology modelling is generation of a 3D model of a target protein on the 
basis of the sequence–structure alignment. At this stage, 3D properties of the modelling target 
can be adjusted, to resemble the real structure as much as possible. For instance, the family A 
of GPCRs is characterized by the presence of cysteine residues involved in the formation of 
extracellular disulfide bridges. It is of importance that the presence of cysteine residues and 
their putative involvement in the formation of disulfide bridges is identified prior to the 
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construction of the model (31). Following the construction, the receptor model can be refined 
using energy minimizations, Monte Carlo simulations, or molecular dynamics simulations. 
These simulations are designed to explore as much of the relevant regions of conformation 
spaces as possible (29). Model refinement is performed to relax high-energy structures and 
remove close contacts between atoms. 
The fourth and final step in homology modelling is estimating the correctness of the resulting 
model. Once a protein model has been built, it is necessary to assess its quality and reliability. 
This can be verified by examining its stereochemical accuracy, packing quality and folding 
reliability. The accuracy of bond lengths, bond angles, torsion angles and the correctness of 
amino acid chirality has to be proved. The interior packing quality of a protein model is a 
major contributor to the stability of the overall conformation and can thus be used to estimate 
its reliability. The folding correctness can be measured by the 3D-Profiles method, an 
approach based on the general principle that the 3D structure of a protein must be compatible 
with its own amino acid sequences (30). 
Evaluation of the model can be performed by online analyzing tools such as SAVES 
(Structural Analysis and Verification Server) at http://services.mbi.ucla.edu/SAVES/, by site 
directed mutagenesis studies based on the model and docking of known binders and decoys to 
the target protein. 
 
 
1.6.3 Docking and scoring 
 
The docking process involves the prediction of ligand conformation and orientation within a 
binding site in a target protein structure or homology model. There are two aims of docking 
studies: accurate structural modelling and correct prediction of affinity/activity. The process 
of docking begins with the application of docking algorithms to place small molecule ligands 
into the active site of a transporter, enzyme or the binding site of a receptor (termed ligand 
poses). These algorithms are additionally complemented by scoring functions that are 
designed to predict the affinity through the evaluation of interactions between compounds and 
potential targets (32,33). The scoring functions can be grouped into three basic types 
according to how they are derived: force field-based, empirical, and knowledge-based. Force 
field-based scoring derives from physical atomic interactions, including van der Waals 
interactions, electrostatic interactions and bond-stretching, bending and torsional forces. 
	 25	
Empirical scoring functions estimate the binding affinity of a complex on the basis of a set of 




where ΔGi represents different energy terms such as van der Waals, electrostatics, hydrogen 
bonding, entropy and hydrophobicity energy terms. Knowledge-based scoring functions 
employ energy potentials derived from structural information embedded in experimentally 
determined atomic structures. Pairwise potentials are directly obtained from the occurrence 
frequency of atom pairs in a database using the inverse Boltzmann relation. The potentials are 
calculated by 
 
w(r) = -kB T ln[g(r)], g(r) = ρ(r)/ρ*(r) 
 
where kB is the Boltzmann constant, T is the absolute temperature of the system, ρ(r) is the 
number density of the protein–ligand atom pair at distance r, and ρ*(r) is the pair density in a 

















2. Aim of the study 
 
The main aim of the project is to use a structure based molecular modelling approach to 
predict the putative interactions of 8 194 chemical substances in the Tox21 (Spring 2012) 
database with serotonergic GPCRs and with the SERT. If the chemical substances interact 
with these proteins, they may interfere with the serotonergic neurotransmission in the brain. 
These proteins are also important CNS drug targets and the chemicals may interfere with the 
effects of CNS drugs.   
Models of serotonergic receptors (5-HT1A, 5-HT2A, 5-HT2C) will be constructed by homology 
modelling with known structures in the PDB database. Newly released X-ray crystal 
structures of the human SERT will also be imported from the PDB and optimized with 
molecular modelling techniques. Molecular docking will be utilized to predict putative 
harmful effects and drug interactions of the toxicants in the Tox21 database with serotonergic 
receptors and the SERT. Known agonists and antagonists will be docked into the receptor 
models as well as inactive compounds with similar physiochemical properties to predict how 
well the models discriminate known binders from decoys. The CNS MPO tool will give 
ranking scores for toxicants, to predict their physicochemical abilities to reach the CNS. This 
study will provide insight into detailed prediction of ligand interactions of serotonergic 

















3.1 Software and databases 
 
3.1.1 Molsoft Internal Coordinates Mechanics (Version 3.8.4) 
 
The Molsoft molecular modelling technology is based on the Internal Coordinate Mechanics 
(ICM) approach which gives a general modelling and structure prediction framework for 
many tasks of structural biology and rational drug design (35). The ICM program was used to 
build homology models of the receptors, and to convert receptor binders and decoys from 
their SMILES code to 2D structures. 
 
 
3.1.2 Schrödinger (Version 2015.3) 
 
Schrödinger is a software company that has developed products for practicing computational 
chemistry. The company provides several software products for molecular modelling and 
molecular design for the use in drug development. Maestro is the graphical user interface 
(GUI) for nearly all of Schrödinger’s computational programs (36). This program was used to 
refine the previously constructed homology models from ICM, and build new receptor models 
based on induced fit docking (IFD). The virtual screening workflow (VSW) option was used 
in the docking of sets of ligands and decoys into the homology models. Python-scripts 




3.1.3 The Protein Data Bank (PDB) 
 
The crystal structures of serotonin receptors, SERT and other homologous proteins of known 
structure (adrenergic and dopaminergic receptors) were downloaded from the PDB 
(http://www.rcsb.org/pdb/home/home.do). The PDB is an archive of information about the 
experimental determined 3D structures of large biological molecules, such as proteins and 
nucleic acids, mostly solved by X-ray crystallography techniques (37). At present, there is 
about 117 000 3D structure complexes in the PDB, of which only around 1 000 are membrane 
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proteins. This makes homology modelling a very important alternative for studying the 
structure of membrane proteins. The PDB archive contains receptor structures that provided 
templates for the receptors studied.  
 
 
3.1.4 UniProt Knowledge-Base 
 
UniProtKB is a database that provides resources of protein sequence and functional 
information (http://www.uniprot.org) (38). Unlike the PDB, which provides the 3D structure 
templates, UniProtKB gives access to the amino acid sequences of the target receptors. All 





ChEMBL is a database containing binding, functional and ADMET (absorption, distribution, 
metabolism, excretion and toxicity) information for a large number of drug-like bioactive 
compounds (39). The ChEMBL database is accessible via a simple interface at: 
https://www.ebi.ac.uk/chembldb. This interface allows users to search for compounds, targets 
or assays of interest in a variety of ways.  
 
 
3.1.6 IUPHAR/BPS Guide to PHARMACOLOGY 
 
The IUPHAR/BPS Guide to PHARMACOLOGY is a database created by the British 
Pharmacological Society (BPS) and the International Union of Basic and Clinical 
Pharmacology (IUPHAR) (http://www.guidetopharmacology.org). This database provides 
pharmacological information of receptors, prescription medicines and experimental drugs that 
act on them (40). 
This database was used to generate ligands known to be active with high affinity for serotonin 




3.1.7 Database of Useful Decoys-Enhanced (DUD-E) 
 
The Database of Useful Decoys-Enhanced (DUD-E) (http://dude.docking.org) was developed 
by Mysinger et al. in 2012 and is an improved version of The Directory of Useful Decoys 
(DUD). The DUD-E is designed to help benchmark molecular docking programs by 
providing challenging decoys (41). It is largely based on the intersection of ChEMBL, for 
ligand annotations and affinities, and the PDB, for structures. This database was used to 




3.1.8 Tox21 database (Version: Spring 2012) 
 
Tox21 is a database library that contains 8 194 environmental chemicals (release Spring 
2012) and approved drugs with a potential to disrupt biological pathways that may result in 
toxicity. Tox21 researchers aim to develop better toxicity assessment methods to quickly and 
efficiently test whether certain chemical compounds have the potential to disrupt processes in 
the human body that may lead to negative health effects (5). The potential binding of the 

















3.2 Homology modelling 
 
3.2.1 Template identification 
 
The X-ray structures chosen as templates were structures with high resolution and a bound 
ligand (agonist or antagonist) included at the binding site. 
In order to construct high quality homology models of the 5-HT1A, 5HT2A and 5-HT2C 
receptors, X-ray structures with high sequence similarities with target receptors were chosen. 
The sequence similarity between the target receptors and the templates are shown in Table 3. 
 
Table 3. Sequence similarity between the targets and their putative templates obtained in Maestro. Templates 
with the highest sequence similarity were used (highlighted in red). 
Targets Agonist bound templates Antagonist bound templates 
5-HT1B 5-HT2B D3 β2 
5-HT1A 17% 15% 47% 23% 
5-HT2A 17% 27% 20% 35% 
5-HT2C 17% 21% 38% 13% 
  
 
Based on the percent sequence similarity, the following templates were downloaded from the 
PDB: 
- Biased agonist bond state: Crystal structure of the chimeric protein of 5-HT2B in 
complex with ergotamine, R-factor of 2.7 Å; PDB ID: 4IB4 
- Agonist bound state: Crystal structure of the chimeric protein of 5-HT1B in complex 
with ergotamine (PSI community target), R-factor of 2.7 Å; PDB ID: 4IAR 
- Antagonist bound state: Crystal structure of human β2-adrenergic G-protein coupled 
receptor, R-factor of 2.4 Å; PDB ID: 2RH1 
- Antagonist bound state: Crystal structure of the human dopamine D3 receptor in 







The X-ray crystal structures of human SERT were also downloaded from the PDB: 
- X-ray structure of the ts3 (human SERT with three thermostabilizing mutations 
Tyr110Ala, Ile291Ala and Thr439Ser) complexed with (S)-citalopram at the substrate 
binding (central) site, R-factor of 3.15 Å; PDB ID: 5I71 
- X-ray structure of the ts3 human SERT complexed with (S)-citalopram at the central 
and allosteric sites, R-factor of 3.24; PDB ID: 5I73 
- X-ray structure of the ts3 human SERT complexed with paroxetine at the central site, 
R-factor of 3.14 Å; PDB ID: 5I6X 
 
 
3.2.2 Sequence alignment 
 
Sequence alignments of serotonergic and melatonin receptors were prepared by using the 
Molsoft ICM program. The templates were aligned to show the conserved regions within the 
serotonergic and melatonin receptors. Melatonin receptors are believed to be structurally quite 
similar to the serotonergic receptors, and it is of interest to study the sequential conservation 
between melatonin receptor and the serotonergic receptors and they were therefore included 
in the alignment.  
For some templates, the T4-lysozyme part of the structure had to be removed by the text 
editor and the gaps in TM helices were adjusted manually in the ICM, all this to make sure 
that the conserved residues in helices and cysteine bridges between the helices were in correct 





Fig. 6. Sequence alignment obtained by the ICM software.  
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3.3 Molecular docking 
 
3.3.1 Generation of binders and decoys 
 
The known binders for the target receptors were downloaded from IUPHAR/BPS database 
into the ICM software. The chemistry module in ICM was used to convert SMILE codes to 
ligand 2D structures. The same tool was used to protonate the aliphatic amino groups of the 
ligands, important for ionic ligand-receptor interactions. The charges were set at a pH of 6.5. 
To generate decoys, the SMILE codes had to be uploaded to the website in the panel: 
Generate à SMILES input (41). According to the website, there are 50 decoys obtained for 
each ligand, and for this to be statistically significant, decoys were generated for 4 times. The 
collected decoy compounds were then imported to the ICM software, where the same 
procedure was performed as for the known binders. Additionally, the duplicate decoys had to 




3.3.2 Preparation of ligands, receptors and transporter for docking 
 
The known binders (previously generated in ICM) for serotonin receptors and the SERT were 
imported to Maestro as an sdf file. These known binders were firstly protonated in ICM (pH 
set to 6.5, as described), such that they could interact with an aspartic acid residue. A salt 
bridge interaction between an Asp present in serotonin receptors and transporter, and the 
protonated amine moiety in ligands is important for binding. The task Ligand Preparation 
(LigPrep) was then used to convert 2D ligand structures to 3D conformations. 
The homology models of serotonin receptors previously constructed in ICM software, and the 
X-ray structures of the SERT (obtained directly from the PDB) were also imported to 
Maestro. These were then prepared by the task Protein Preparation (ProteinPrep). ProteinPrep 
adjusts missing hydrogen atoms, builds in missing residues and loops, identifies overlapping 





3.3.3 Induced fit docking (IFD) 
 
Induced fit docking (IFD) is a molecular docking method that can predict ligand binding 
modes and concomitant structural changes in the receptor. Unlike other docking methods that 
assume a rigid receptor, in IFD receptors adopt the binding site to conform to the shape and 
binding mode of the ligand. Schrödinger’s Maestro possesses Prime and Glide modules that 
account for possible binding modes and associated conformational changes within receptor 
binding sites. These two modules were applied in the IFD protocol.  
When ligand and protein preparation were conducted, we were ready to run an IFD. 
To perform IFD, known binders with high affinity for each of the 5-HT1A, 5-HT2A and 5-HT2C 
receptors were selected. The purpose was to optimize the binding pocket in each of the 
receptor models in complex with a high affinity binder. The important interaction between the 
carboxylate oxygen atom(s) in Asp3.32 (Ballesteros-Weinstein numbering scheme) in TM 
helix III (the amino acid conserved in all amine GPCRs) and the protonated amine of ligands 
was included. Inserting a constraint (Asp), implies requirement for a ligand to make a 
hydrogen bond with the carboxylate oxygen atom(s) of Asp3.32 in the receptor. The choice of 
ligands was made upon their mechanism of action (agonist/antagonist), affinity and 
sometimes selectivity for the target receptor. An overview of the target receptors and the 






Table 4. Showing high affinity binders chosen for IFD and constraints of target receptors. Affinity values 
imported from www.guidetopharmacology.org (40).  
Receptor Constraint* Ligand Pharmacological 
activity 
Affinity (pKi) 
5-HT1A Asp 116 LY293284 Full agonist 10.1 
  rec 15/3079 Antagonist 9.7 
5-HT2A Asp 155 methylergonovine Full agonist 9.4 
  asenapine Antagonist 10.2 
5-HT2C Asp 134 YM348 Full agonist 9.0 
  serindole Inverse agonist 9.0 – 9.2 
* carboxylate oxygen – protonated amine hydrogen in all aspartic acid residues. 
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IFD was run by the commands in Maestro as follow: Task à Docking à IFD à Browse 
high affinity ligand à Receptor centroid of selected residues: Constraint Asp3.32 à Protein 
preparation constrained refinement (PPCR) à Glide redocking: 20 à Jobs: Number of Glide 
50; Number of Prime 50 à Run. 
 
 
3.3.4 Virtual screening workflow (VSW) 
 
The IFD generated conformations of the models were then used for docking the entire library 
of binders and decoys using the virtual screening workflow (VSW). Like regular docking and 
IFD, the VSW is also a molecular docking method for predicting ligand binding to a target 
receptor. The VSW assumes a rigid receptor and can assay a very large number of 
compounds. 
Docking of decoys and active ligands was performed in Maestro by the following commands: 
Docking à VSW à Input of prepared actives/decoys à Remove LigPrep option à 
Receptor: Add in grids à Docking (SP Glide): Option 100% à Job write.  
The job was then written in the directory as an input file. The input file was run on the 
command line in Linux (computer operating system) terminal, where the add_constraint.sh 
and features.txt scripts were added. The add_constraint.sh file was added to the input file to 
ensure the crucial interactions between the conserved Asp3.32 carboxylate group and the 
protonated amine in the actives/decoys, when docked. On the other hand, feature.txt is the 
constraint for both receptor and actives/decoys, where CONSTRAINT_GROUP is the 
constraint from the receptor side and FEATURE for actives/decoys. The feature.txt script had 
to be edited in the following way: 
 
[[CONSTRAINT_GROUP:1]] 
        USE_CONS   hbond1:1, 
        NREQUIRED_CONS   ALL 
    [[FEATURE:1]] 
        PATTERN1   "[#1][NH+] 1 include" 
 PATTERN2   "[#1][NH2+] 1 include" 




3.3.4 Evaluation of models with BEDROC 
 
BEDROC is a statistical approach used to evaluate the performance of ranking methods in 
virtual screening (VS) (42). To create BEDROC, the robust initial enhancement (RIE) and 
receiver operating characteristic curve (ROC) metrics were combined. This implied the 
BEDROC metric to receive the discrimination power of the RIE metric and the statistical 
significance from ROC. The problem of the ROC metric alone was the “early recognition 
problem” and this disadvantage is compensated by the RIE. A successful VS must rank 
actives early in the set of compounds since a very small proportion of the compounds will be 
tested experimentally (42).  
BEDROC was used to statistically evaluate how the different homology models differentiate 
between actives and decoys. This task had to be performed in the Linux main terminal. The 
following command is an example of how the task was performed in the main terminal:  
 
$SHRODINGER/run ~/script_used/enrichment_runner.py –n 20 –l ../../ligands/*.mae –d 



















3.3.5 Glide docking calculations with exogenous toxicants  
 
The homology models with the highest BEDROC scores (after the VSW of binders and 
decoys) were used for docking of the compounds in the Tox21 database (9 757 after LigPrep) 
by using Glide. The protein prepared structures of SERT were directly Glide docked with 
both the known binders (inhibitors) and toxicants, but without use of the constraint option in 
Maestro. Glide approximates a complete systematic search of the conformational, 
orientational, and positional space for the docked ligands (43).  
The toxicants were imported to Maestro as an sdf file and the compounds were prepared 
following the same procedure as for the binders and decoys (described in section 3.3.2). 
This was achieved by choosing the following options in Maestro: Tasks à LigPrep à 
Browse sdf file of the toxicants à Generate possible states at target pH – 6.5 à Desalt and 
generate tautomers options – Removed à Generate specified chiralities at most 2 per ligand 
à Run.  
The toxicants that have obtained the best Glide score were then visually inspected to study 
their interaction mode with the target models and the SERTs, and if these interactions 
resemble those of the known binders.  
 
					 	
Fig. 7. Right – An overview of the steps utilized in the project described in sections 3.2 and 3.3. Left – An 
example of a receptor-ligand complex in 5-HT2C receptor modelled (final stage). The backbone atoms of the 
receptor are shown. 
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3.4 Prediction of the BBB passage by CNS MPO tool 
 
In 2010 Wager et al developed a novel medicinal chemistry tool named Central Nervous 
System Multiparameter Optimization (CNS MPO) (44). This tool is based on a set of 
physicochemical properties with purpose of enabling greater flexibility in CNS compound 
design beyond the use of a single parameters, expanding design space, and enhancing the 
odds of identifying compounds. The CNS MPO algorithm accounts a set of 6 fundamental 
physicochemical parameters (ClogP, ClogD, MW, TPSA, HBD, and pKa) and a variation of 
Harriongton’s optimization method, which is a summation of the individual components to 
yield a composite desirability score. 
The CNS MPO tool was applied in this project to predict the physicochemical properties of 
the environmental toxicants and drugs of the Tox21 database in order to predict if they have 























4.1 Homology models 
 
A total of 6 receptor models were built by using the homology modelling in ICM (Fig. 8). The 
models were agonist and antagonist bound states of 5-HT1A, 5-HT2A and 5-HT2C receptors.  
The agonist bound 5-HT1A receptor model was constructed with the 5-HT1B receptor structure 
(PDB ID: 4IAR) as the template, while the other two agonist bound models were constructed 
with the 5-HT2B receptor structure (PDB ID: 4IB4). The antagonist bound 5-HT2A receptor 
model was constructed from a β2 receptor structure (PDB ID: 2RH1), while the antagonist 
bound 5-HT1A and 5-HT2C receptor models were constructed from the dopamine D3 receptor 
structure (PDB ID: 3PBL). A model refinement was performed for all these models, and 
protein health score was predicted. The protein health calculates the energy strain of a 
structure. The protein health score was < 6 for all residues in binding pockets, which is 
considered as good, while some residues in loops showed protein health score > 6. However, 
the binding pockets were in focus, and loop modelling to improve loop quality was not 
prioritized. The scores indicate high quality models that can be used for docking. 
For further optimizations of the models and binding pockets, the models were imported to 









					 					5-HT1A	agonist	bound	state	 	 	 	 		5-HT1A	antagonist	bound	state	
																										 														 	
					 					5-HT2A	agonist	bound	state	 	 	 	 		5-HT2A	antagonist	bound	state	
																																						 	
					 					5-HT2C	agonist	bound	state	 	 	 	 		5-HT2C	antagonist	bound	state	
Fig. 8. Models of agonist and antagonist bound states of serotonin receptors obtained in ICM and protein 
prepared in Maestro. The backbone of the receptor models is shown. The extracellular side is up in the 
illustrations. 
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4.2 Molecular docking 
 
4.2.1 Results from BEDROC calculations 
 
BEDROC calculations were used to evaluate how the homology models differentiate between 
actives (known binders) and decoys. The BEDROC values were obtained for each of the 
receptor output model from IFD, and the 6 best BEDROC-curves (one for each receptor 
model) are presented in Fig. 9. The best model of 5-HT1A agonist bound state had a BEDROC 
value of 0.563, while the best model for antagonist bound state of the same receptor had a 
BEDROC value of 0.685. The best model of 5-HT2A agonist bound state had a BEDROC 
value of 0.828, while the best model for antagonist bound state had a BEDROC value of 
0.498. The best model of 5-HT2C agonist bound state had a BEDROC value of 0.563, while 































	 	5-HT2C	agonist	bound	state:	Model	8	 	 	 	5-HT2C	antagonist	bound	state:	Model	11	
	
	
Fig. 9. BEDROC-curve for each of the three serotonin receptors (agonist/antagonist bound), showing the scoring 
values of ligands and decoys. X-axis represents the ranking of the ligand set (specificity). Y-axis represents the 
number of actives scored (sensitivity). 
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4.2.2 Induced fit docking 
 
The IFD was performed by choosing known high affinity binders for receptor models. The 
scoring results of the best models (selected based on the highest BEDROC score) are given in 
Table 5.  
 
Table 5. Scoring values of known binders in homology models. Negative scores indicate stronger interactions 
with the receptor. Affinity values imported from www.guidetopharmacology.org (40). 
Receptor Ligand IFD score Glide score Affinity (pKi) 
5-HT1A LY293284 -478.63 -6.35 10.1 
 rec 15/3079 -467.76 -9.00 9.7 
5-HT2A methylergonovine -521.70 -9.21 9.4 
 asenapine -504.67 -7.09 10.2 
5-HT2C YM348 -541.02 -8.23 9.0 
 serindole -485.75 -9.83 9.0 – 9.2 
 
The IFD step was important for optimizing the binding pockets of the models and for 
clarifying the models for docking of known binders and toxicants into the best outputs. The 
IFD resulted in the generation of new receptor complexes (outputs), which were used for 
further docking. The IFD gave a varying number of receptor-ligand complexes as output 
between the different receptors. The 5-HT1A antagonist bound receptor yielded 16 new model 
complexes, the 5-HT1A antagonist bound receptor yielded 17 new model complexes, the  
5-HT2A agonist bound receptor yielded 32 new model complexes, the 5-HT2A antagonist 
bound receptor yielded 36 new model complexes, the 5-HT2C agonist bound receptor yielded 
32 new model complexes and the 5-HT2C antagonist bound receptor yielded 41 new model 
complexes.  
One agonist and one antagonist conformational state for each receptor model (selected by the 
best BEDROC score) was later utilized for docking of the toxic compounds in the Tox21 










Fig. 10. 3D representation of ligand interactions of the best homology models obtained by IFD with known 
binders. Residues within 3Å sphere radius of the docked ligand are shown. Interactions are marked off with 





				 	 										 	
	 	 	 	 Known	binder:	asenapine	(R)	
	 	 	 	 5-HT2A	antagonist	bound	receptor:	Model	27	from	IFD	
	
Fig. 11. 3D representation of ligand interactions of the best homology models obtained by IFD with known 
binders. Residues within 3Å sphere radius of the docked ligand are shown. Interactions are marked off with 






	 	 	 	 Known	binder:	sertindole	(R)	
	 	 	 	 5-HT2C	antagonist	bound	receptor:	Model	11	from	IFD	
	
Fig. 12. 3D representation of ligand interactions of the best homology models obtained by IFD with known 
binders. Residues within 3Å sphere radius of the docked ligand are shown. Interactions are marked off with 
dashed line: blue/turquoise = aromatic, green = π-cation, purple = H-bonds.  
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4.2.3 Docking of known binders into receptor models obtained by IFD 
 
The known binders and decoys were docked into the new conformations (one for each 
receptor) by the VSW to predict their binding to the target receptors. The number of known 
binders docked in 5-HT1A agonist bound state was 82 agonists with 19 857 decoys. 5-HT1A 
antagonist bound state was docked with 61 known antagonists and 10 119 decoys, 5-HT2A 
agonist bound state with 66 known agonists and 12 873 decoys, 5-HT2A antagonist bound 
state with 55 known antagonists and 9 851 decoys, 5-HT2C agonist bound state with 70 known 
agonists and 13 446 decoys, and 5-HT2C antagonist bound state with 89 known antagonists 
and 19 328 decoys. 
The 10 best Glide score results of the known binders were chosen to predict how the Glide 







Table 6. Showing the 10 compounds of the known binders with best Glide score for the 5-HT1A receptor models. 
Mean score of the 10 compounds was set to be a threshold value for scoring of the toxicants. Some ligands 
appear more than one time due to the R and S configuration states. Affinity values imported from 
www.guidetopharmacology.org (40). 
5-HT1A agonist bound state 
(model 7) 
 5-HT1A antagonist bound state 
(model 5) 








"L-772,405" -8.34 7.2*  "(S)-flurocarazolol" -9.17 7.5 
"L-694,247" -8.12 9.3  "(S)-flurocarazolol" -8.65 7.5 
"lisuride" -7.70 9.7 - 9.8  "ketanserin" -8.51 5 
"FG-5893" -7.69 8.7  "rec 15/3079" -8.50 9.7 
"rizatriptan" -7.67 6.4  "(R)-flurocarazolol" -8.46 6.5 
"L-772,405" -7.66 7.2* "WAY-100635" -8.39 7.9 – 9.2 
"5-CT" -7.63 9.4 - 10.3  "[3H]p-MPPF" -8.27 8.4** 
"LY334370" -7.55 7.8  "pipamperone" -8.25 5.6 
"donitriptan" -7.48 7.6  "(-)-propranolol" -8.14 7.5 
"eletriptan" -7.34 7.4  "pindolol" -8.08 8.1 
Mean score -7.72   Mean score -8.44  
*- these affinity values have pIC50 unit. 
**- these affinity values have pKd unit. 
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Table 7. Showing the 10 compounds of the known binders with best Glide score for the 5-HT2A receptor models. 
Mean score of the 10 compounds was set to be a threshold value for scoring of the toxicants. Affinity values 
imported from www.guidetopharmacology.org (40). 
5-HT2A agonist bound state 
(model 2) 
 5-HT2A antagonist bound state 
(model 27) 








"donitriptan" -9.79 6.7  "methiothepin" -7.86 8.5 
"5-CT" -8.86 6.5  "cyamemazine" -7.55 8.8 
"AL-37350A" -8.81 8.7  "fluspirilene" -7.48 8.0 
"Ro 60-0175" -8.74 7.4  "pimozide" -7.48 7.1 - 7.7 
"tryptamine" -8.72 7.1  "mianserin" -7.33 7.7 - 9.6 
"BW723C86" -8.60 7.2 "metergoline" -7.20 8.6 
"lisuride" -8.52 8.6  "risperidone" -6.90 9.3 - 10.0 
"terguride" -8.51 8.3  "clozapine" -6.88 7.6 - 9.0 
"5-MeOT" -8.46 8.9  "asenapine" -6.86 10.2 
"5-hydroxy-
tryptamine" 
-8.23 8.9  "pipamperone" -6.77 8.3 


















Table 8. Showing the 10 compounds of the known binders with best Glide score for the 5-HT2C receptor models. 
Mean score of the 10 compounds was set to be a threshold value for scoring of the toxicants. Some ligands 
appear more than one time due to the R and S configuration states. Affinity values imported from 
www.guidetopharmacology.org (40). 
5-HT2C agonist bound state 
(model 8) 
 5-HT2C antagonist bound state 
(model 11) 








"5-CT" -7.87 5.2 - 6.7  "trifluoperazine" -9.04 6.4 
"aripiprazole" -7.83 7.6  "trifluoperazine" -8.68 6.4 
"YM348" -7.60 9.0  "zotepine" -8.64 8.6 
"YM348" -7.58 9.0  "chlorpromazine" -8.38 7.6 - 8.2 
"Ro 60-0175" -7.45 7.7 - 8.2  "amitriptyline" -8.37 8.1 
"S 16924" -7.37 7.7 "sertindole" -8.11 9.0 - 9.2 
"RU 24969" -7.23 6.8  "mesulergine" -8.10 8.7 - 9.3 
"BRL-15572" -7.21 6.2  "volinanserin" -7.99 7.5 - 7.7 
"VER-3323" -7.15 8.2  "clozapine" -7.83 7.4 - 8.7 
"TFMPP" -7.10 6.5 - 7.8  "perphenazine" -7.83 6.9 
Mean score -7.44   Mean score -8.30  
 
 
4.2.4 Docking of known binders into crystal structures of SERT 
	
The know binders (inhibitors) of SERT were directly docked with Glide into all three protein 
prepared structures of SERT (PDB ID: 5I6X; 5I71; 5I73). No constraint option was added for 
docking, such that ligands could freely orient in the binding pocket to obtain the best free 
energy of binding.  
The 10 best Glide score results of the known binders were chosen to predict how the Glide 









Table 9. Showing the 10 compounds of the known binders with best Glide score for the orthosteric binding site 
in SERT (PDB ID: 5I6X). Mean score of the 10 compounds was set to be a threshold value for scoring of the 
toxicants. Some ligands appear more than one time due to the R and S configuration states. Affinity values 
imported from www.guidetopharmacology.org (40). 
SERT orthosteric binding site 
(PDB ID: 5I6X) 
Known binders Glide score (kcal/mol) Affinity (pKi) 
"[3H]paroxetine" -9.73 9.7** 
"paroxetine" -9.56 9.6 
"fluoxetine" -9.09 8.5 
"fluoxetine" -9.02 8.5 
"[3H]citalopram" -9.00 8.3** 
"citalopram" -9.00 8.4 
"[3H]citalopram" -8.87 8.3** 
"escitalopram" -8.87 9.0* 
"citalopram" -8.87 8.4 
"vortioxetine" -8.83 8.8 
Mean score -9.08  
*- these affinity values have pIC50 unit. 


















Table 10. Showing the 10 compounds of the known binders with best Glide score for the orthosteric binding site 
in SERT (PDB ID: 5I71). Mean score of the 10 compounds was set to be a threshold value for scoring of the 
toxicants. Some ligands appear more than one time due to the R and S configuration states. Affinity values 
imported from www.guidetopharmacology.org (40). 
SERT orthosteric binding site 
(PDB ID: 5I71) 
Known binders Glide score (kcal/mol) Affinity (pKi) 
"vilazodone" -9.60 8.8 - 9.3* 
"fluvoxamine" -9.23 8.7** 
"fluvoxamine" -9.23 8.7** 
"lofepramine" -9.15 7.2 
"[3H]citalopram" -9.12 8.3** 
"escitalopram" -9.12 9.0* 
"citalopram" -9.12 8.4 
"[3H]citalopram" -9.09 8.3** 
"citalopram" -9.09 8.4 
"protriptyline" -8.98 7.7** 
Mean score -9.17  
*- these affinity values have pIC50 unit. 


















Table 11. Showing the 10 compounds of the known binders with best Glide score for the allosteric binding site 
in SERT (PDB ID: 5I73). Mean score of the 10 compounds was set to be a threshold value for scoring of the 
toxicants. Some ligands appear more than one time due to the R and S configuration states. Affinity values 
imported from www.guidetopharmacology.org (40). 
SERT allosteric binding site 
(PDB ID: 5I73) 
Known binders Glide score (kcal/mol) Affinity (pKi) 
"nefazodone" -8.45 6.7** 
"vilazodone" -8.19 8.8 - 9.3* 
"lofepramine" -8.14 7.2 
"desipramine" -7.74 7.7 
"desipramine" -7.74 7.7 
"lofepramine" -7.73 7.2 
"amoxapine" -7.50 7.7 
"ziprasidone" -7.48 7.3 
"nortriptyline" -7.46 8.2 
"dosulepin" -7.38 8.1 
Mean score -7.78  
*- these affinity values have pIC50 unit. 
**- these affinity values have pKd unit. 
 
 
4.2.5 Screening scores for exogenous toxicants 
 
The total of 9 757 ligand prepared toxicants were docked into constructed serotonergic 
receptor models and protein prepared structures of SERT. Out of 9 757 toxicants, 6 803 had a 
CNS MPO score ≥ 4. 
 
For serotonergic receptor models the mean Glide scores of the 10 best Glide score results 
(Tables 6, 7 and 8) of the known binders were used as a threshold. Toxicants with a score 
better than the threshold value for known binders were considered as putative binders for the 
target. The number of toxicants that exceeded threshold mean score for each receptor model is 





Table 12. Showing the number of toxicants that exceeded the threshold mean score. 
Receptor model Mean Glide score Number of toxicants over threshold 
5-HT1A agonist bound -7.72 33 
5-HT1A antagonist bound -8.44 57 
5-HT2A agonist bound -8.72 4 
5-HT2A antagonist bound -7.23 186 
5-HT2C agonist bound  -7.44 74 
5-HT2C antagonist bound -8.30 144 
 
 
The 10 best Glide score results of the toxicants for each receptor model were also presented 
(Appendix, A1). From these tables, the toxicants with the highest CNS MPO score were 
selected for detailed inspection (Table 13 and Fig. 13).  
 
Table 13. Showing toxicants that gained the best CNS MPO and Glide score for the receptor models. 
Toxicant CNS MPO Glide score Target 
zelandopam 4.16 -8.18 5-HT1A 
cetrizine amide 4.86 -9.15 5-HT1A 
safrazine 5.50 -8.98 5-HT2A 
eletriptan 4.13 -8.60 5-HT2A 
rac nebivolol 4.17 -8.05 5-HT2C 










Toxicant:	safrazine	 	 	 	 	 	 	Toxicant:	eletriptan	
5-HT2A	agonist	bound	receptor:	Model	2	from	IFD	 	 	 	5-HT2A	antagonist	bound	receptor:	Model	27	from	IFD	
	
Toxicant:	rac	nebivolol	 	 	 	 	 	Toxicant:	trifluperidol	
5-HT2C	agonist	bound	receptor:	Model	8	from	IFD	 	 	 	5-HT2C	antagonist	bound	receptor:	Model	11	from	IFD	
	
	
Fig. 13. The toxicant-receptor complexes of the models with the toxicants that gained the best CNS MPO and 
Glide score. The amino acid residues are in a 3Å sphere radius around the toxicants. 
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The protein prepared structures of SERT were also docked with known binders (inhibitors) 
and toxicants without use of the constraint option in Maestro.  
For SERT structures the mean Glide scores of the 10 best Glide score results (calculated in 
Tables 9, 10 and 11) of the known binders were used as a threshold. The number of toxicants 
that exceeded the threshold mean score for each SERT structure is shown in Table 14. 
 
Table 14. Showing the number of toxicants that exceeded the threshold mean score. 
X-ray crystal structure Mean Glide score Number of toxicants over threshold 
SERT (PDB ID: 5I6X) -9.08 114 
SERT (PDB ID: 5I71) -9.17 207 
SERT (PDB ID: 5I73) -7.78 370 
 
 
The 10 best Glide score results of the toxicants for each SERT structure were also selected 
(Appendix, A2) for further analysis. However, none of the 10 selected toxicants, except for 
bamifylline which was 9th on the Glide score list (Appendix, A2, Table b), had a CNS MPO 
score ≥ 4. The selected vicriviroc was 29th on the Glide score list and trelanserin was 54th on 
the Glide score list. 
The SERT complexes with the toxicants that gained the best CNS MPO and Glide scores are 





















Fig. 14. SERT (S)-citalopram bound (central site) in complex with the known binder and the toxicant that gained 
the best CNS MPO and Glide score. The amino acid residues are in a 3Å sphere radius around the known binder 











Fig. 15. SERT paroxetine bound (central site) in complex with known binder and toxicant that gained the best 
CNS MPO and Glide score. The amino acid residues are in a 3Å sphere radius around the known binder and the 










Fig. 16. SERT (S)-citalopram bound (allosteric site) in complex with known binder and toxicant that gained the 
best CNS MPO and Glide score. The amino acid residues are in a 3Å sphere radius around the known binder and 




In the present project we have constructed theoretical homology models of the 5-HT1A,  
5-HT2A and 5-HT2C receptors and optimized the X-ray crystal structures of SERT for docking 
by molecular modelling techniques. The optimized models were used for docking of known 
binders for these important drug targets, and for predicting the ligand-receptor interactions of 
8 164 exogenous toxicants from the Tox21 database.  
 
As of today, there is no available crystal structures for 5-HT1A, 5-HT2A and 5-HT2C receptors. 
The homology modelling approach was the method chosen for predicting the 3D structure of 
these receptors. The models were constructed by using known receptor structures as templates 
with similar biological and chemical properties imported from the PDB. High sequential 
similarity between the model targets and the available X-ray crystal structures of 5-HT1B,  
5-HT2B, D3 and β2 (Table 3) has enabled a reliable homology modelling. However, a certain 
degree of template bias will always be present, as the templates are not completely identical to 
structure of the receptors constructed.  
Sequence alignments of serotonergic and melatonin receptors were performed in order to 
show the conserved regions. High amino acid conservation between melatonin and serotonin 
receptors was observed in all TMHs (Fig. 6). Their structural similarity could indicate their 
similar interactions to environmental toxicants, which might lead to potential physiological 
consequences. 
 
The sequences of target receptors were aligned with different crystal structures to accordingly 
yield an agonist and antagonist bound state for each receptor (Fig. 8). This was done due to 
the differences in the size of the binding pockets, where we assumed that an antagonist bound 
state have somewhat bigger binding site relative to the agonist bound state. This ensured that 
some molecules of bigger size could be docked into the receptor models. 
The protein health score of serotonergic receptors (in the binding pockets) was < 6 after ICM 
refinements. The protein health value < 6 means that the strain energy of structures is 
acceptable. The models were further optimized by IFD, while the X-ray crystal structures of 
SERT were directly prepared for Glide docking, and IFD was not performed for the SERT 
structures. As the focus was on the binding pockets, the loop regions were neglected in the 
homology modelling process. However, loops are highly flexible parts of the receptors, and 
sometimes they can be important in the ligand-receptor interactions.  
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The docking and scoring calculations performed were based on Prime and Glide modules 
integrated in Maestro program. In the IFD protocol, a particular ligand (high affinity binder) 
was docked with Glide to the protein prepared receptor structure, with many poses generated. 
Prime was used to optimize the receptor structure with each particular ligand pose (the 
induced-fit part). The ligand was then redocked into the new receptor conformations, and the 
complexes were scored based both on the redocking Glide score and the Prime energy from 
the optimization.  
The scoring functions Glide and Prime are considered to have very good performance at 
predicting if the ligand can bind or not, but they are not so reliable for prediction of the 
ligands free energy (ΔG). 
Different IFD and Glide scores were calculated for serotonergic receptor models docked with 
high affinity binders. As the more negative scores indicate stronger interactions with the 
receptor, the best IFD score was -541.02 for the 5-HT2C receptor docked with YM348 and the 
best Glide score was -9.83 for 5-HT2C receptor docked with serindole (Table 5). IFD and 
Glide scores for docking of the other models also performed well. Seemingly, Glide scores 
for 5-HT1A receptor docked with LY293284 (-6.35) and for 5-HT2A receptor docked with 
asenapine (-7.09) were somewhat lower than expected, relative to their experimentally 
determined affinity values (10.1 and 10.2 pKi). 
One of the approaches utilized for docking to serotonergic receptors, was to include the 
crucial constrained interaction between the carboxylate oxygen atom(s) in Asp3.32 in TM 
helix III and the protonated amine of ligands (Figs. 10, 11 and 12). It was important to include 
this constraint to obtain realistic poses in the docking calculations. Ligand-receptor 
complexes presented in these figures indicate that besides aspartic acid, there is a frequent 
aromatic interaction between the benzene ring in ligands and phenylalanine (Phe) from 
receptors side. Serine (Ser242 in TMH V) from 5-HT2A receptor makes hydrogen bond 
interaction to an amine in the ligand methylergonovine, while tyrosine (Tyr118 in TMH III) 
in 5-HT2C receptor makes hydrogen bond interaction to a carbonyl group in the ligand 
sertindole, and asparagine (Asn273 in TMH VI) from 5-HT2C receptor makes hydrogen bond 
interaction to a cyclic ether in the ligand YM348 (Fig. 12). 
To evaluate the constructed models of serotonergic receptors, the known binders and decoys 
were docked by the VSW. All the serotonergic receptor models performed good at 
differentiating between actives and decoys, with BEDROC values ranging from 0.498 (for 
antagonist bound state of 5-HT2A) to 0.828 (for agonist bound state of 5-HT2A). However, not 
all the actives could be docked into receptor models, and that could be seen in the case of 
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antagonist bound state of 5-HT2C receptor (Fig. 9, down-left corner). This is probably a result 
of a too small binding pocket, since antagonist actives generally are molecules of bigger size 
than agonists. It is important to mention that BEDROC metric can not recognize if the size of 
the binding pockets modelled is real. If the binding pockets modelled are too big, the 
compounds which naturally wouldn’t bind will be docked. 
The BEDROC values, however, suggest that all the constructed models are predictive, and 
thus can be used for docking studies to examine the ligand-receptor interactions of the 
environmental toxicants.  
 
The total of 9 757 ligand prepared toxicants (originally 8 164 before LigPrep that also 
generates enantiomers) were docked into serotonergic receptor models and the protein 
prepared structures of SERT. Out of 9 757 toxicants, 6 803 had a CNS MPO score ≥ 4. A 
CNS MPO score ≥ 4, indicates that a ligand has CNS drug-like properties, and might be able 
to reach the CNS. Accordingly, around 70 % of all the toxicants in the Tox21 database have 
such physicochemical properties and could possibly interfere with neurotransmission in the 
brain.  
To be able to predict the interactions of environmental toxicants with the constructed 
serotonergic receptors and the SERT models, we had to firstly inspect their interactions with 
the known binders. It was observed that most of the 10 compounds with most favourable 
scoring also had strong experimentally determined affinity values (Tables 6, 7 and 8). The 
mean Glide score of known binders was calculated to establish a threshold value for the 
docking of the toxicants. The threshold value was simply utilized to get an insight on how 
many toxicants have the potential of making interactions with serotonergic receptors and the 
SERT. Toxicants with a score better than the threshold value for known binders were 
considered as putative binders for the target. They ranged from 4 toxicants over threshold 
Glide score -8.72 for 5-HT2A agonist bound receptor (Table 12), to 370 toxicants over 
threshold Glide score -7.78 for SERT (PDB ID: 5I73) (Table 14). 
 
The CNS MPO score was used in combination with the Glide score to select out toxicants 
with higher risk to reach and affect serotonergic receptors and the SERT in the CNS.  
It could be observed that important interactions between toxicants and serotonergic receptors, 
similarly to the known binders, are in many cases aromatic interactions with the amino acid 
residue phenylalanine (Fig. 13). In model 7 from IFD of the 5-HT1A agonist bound receptor, it 
was observed that both the known binder (LY293284) and the toxicant (zelandopam) make 
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interactions to Asp116 (TMH III) and Phe235 (TMH VI) (Figs. 10 and 13). In model 5 of 5-
HT1A antagonist bound receptor, both the known binder (rec 15/3079) and the toxicant 
(cetrizine amide) make similar interactions to Asp116 (TMH III) and Phe361 (TMH VI). In 
model 2 of 5-HT2A agonist bound receptor, the known binder (methylergonovine) makes 
interactions to Asp155 (TMH III), Ser242 (TMH V) and Phe335 (TMH VI), while the only 
common interaction of the toxicant (rec nebivolol) is to Asp155, and the other dissimilar 
interaction (ionic) is to Phe334 (TMH VI) (Figs. 11 and 13). In model 27 of 5-HT2A 
antagonist bound receptor, both the known binder (asenapine) and the toxicant (trifluperidol) 
bind to Asp155 (TMH III) and Phe340 (TMH VI). Asenapine binds in addition to Phe339 
(TMH VI). In model 8 of 5-HT2C agonist bound receptor, it was observed that the known 
binder (YM348) binds to Asp134 (TMH III), Phe270 (TMH VI) and Asn273 (TMH VI). 
However, only the constrained Asp134 interaction is present between the toxicant (safrazine) 
and the receptor (Figs. 12 and 13). In model 11 of 5-HT2C antagonist bound receptor, the 
known binder (sertindole) makes interactions to Tyr118 (TMH II), Asp134 (TMH III), 
Phe327 (TMH VI) and Phe328 (TMH VI). Of these, the toxicant (eletriptan) interacts only 
with Asp134 and Phe327. 
 
For the protein prepared structures of SERT, Glide scores of known binders were generally 
better than those of serotonergic models (Tables 9 and 10), except for the allosteric structure 
of SERT (Table 11). The correlation between the Glide scores and the experimental affinity 
values was also very good. 
The Glide scores of toxicants for SERT structures (Appendix, A2) were better relative to the 
Glide scores of toxicants for serotonin receptor models (Appendix, A1). 
The SERT receptor structures were docked without the constraint option, such that ligands 
could freely orient in the binding pocket to obtain the best free energy of binding. The 
interactions between known binders and SERT and toxicants and SERT are presented in Figs. 
14, 15 and 16. The important hydrogen bond interaction between the protonated aliphatic 
amine in ligands and the carboxylate oxygen atom of Asp98 (TMH I) in transporter is present 
in all the complexes. Similarly, as for the serotonergic receptors, aromatic interactions with 
phenylalanine is also present in some ligands. Ligand interactions with tyrosine (Tyr) and 
arginine (Arg) were also observed to be present in some of the complexes. 
In the SERT structure co-crystallized with (S)-citalopram at the central site, the known binder 
(vilazodone) makes interactions with Asp98 (TMH I), Phe335 (TMH VI), Phe341 (TMH VI), 
Arg104 (TMH I) and Asn177 (TMH III). Of these, the toxicant (vicriviroc) interacts with 
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Asp98 (TMH I) and Arg104 (TMH I) (Fig. 14). In the SERT structure co-crystallized with 
paroxetine at the central site, the known binder ([3H] paroxetine) interacts with Asp98 (TMH 
I), Phe341 (TMH VI) and Tyr176 (TMH III), while the toxicant (bamifylline) makes similar 
interactions to Asp98 (TMH I) and Phe341 (TMH VI). In the SERT structure co-crystallized 
with (S)-citalopram at the allosteric site, the known binder (vilazodone) interacts with both 
Asp98 (TMH I) (important for central site) and Asp328 (TMH VI) (important for allosteric 
site), with this stretching out to both the orthosteric and allosteric sites, and Arg104 (TMH I). 
Of these, the toxicant (trenlanserin) was able to interact with Asp98 (TMH I) and Arg104 
(TMH I). However, the toxicant failed to get docked at the allosteric site and make the crucial 
interaction to Asp328 (TMH VI). 
 
In the work presented, many toxic compounds from the Tox21 database were predicted to 
interact with serotonergic receptors and the SERT. Potential interaction of environmental 
toxicants could affect the actions of neurotransmitters, drugs, hormones and inflammatorial 
mediators. Many environmental toxicants had CNS MPO ≥ 4 and are likely to cross the BBB 
and reach the CNS.  
The serotonergic system is a very important drug targeting field, and it is of great interest to 
understand the structural and functional properties of its receptors and transporters.  
Cumulative evidences suggest that 5-HT1A, 5-HT2A and 5-HT2C receptors and SERT have a 
role in pathology of depression and they might be a key for future development of more 
efficacious and faster acting drugs. Many of the known binders tested in this study are 
approved antidepressants and their interactions and physicochemical properties were 
important for analysis of the environmental toxicant’s ability to interfere with the CNS 












The homology modelling approach has its weaknesses and errors, and the generated models 
may have uncertainties influenced by the profound impacts of the utilized templates. The 
constructed models of serotonergic receptors were, however, able to differentiate between 
actives and decoys and the BEDROC scores proved the models to be predictive. 
Detailed interaction analysis of the selected compounds of serotonergic receptors and the 
SERT indicate that besides the crucial interaction with the conserved aspartic acid, aromatic 
interactions with phenylalanine are also very important. The obtained high CNS MPO scores 
and similar Glide scores between the known high affinity binders and toxicants could suggest 
harmful effects and drug interactions in serotonergic system of the CNS.  
Future studies should include in vitro tests of the high ranking environmental toxicants for 
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5-HT1A agonist bound state (model 7) 













phenylpiperidin-4-yl)-1,1-dimethylurea hydrochloride (1:1)" 
-8.20 



















5-HT1A antagonist bound state (model 5) 
Toxicants Glide score 
(kcal/mol) 




"Nelfinavir mesylate" -9.44 
"Nelfinavir mesylate" -9.44 
"Oxatomide" -9.41 
"Manidipine dihydrochloride" -9.27 
"Flunarizine" -9.18 
"Cetirizine amide dihydrochloride" -9.15 






5-HT2A agonist bound state (model 2) 
Toxicants Glide score 
(kcal/mol) 
"Spiperone" -9.55 
"Safrazine hydrochloride" -8.98 
"Carvedilol tartrate" -8.83 











5-HT2A antagonist bound state (model 27) 
Toxicants Glide score 
(kcal/mol) 








"Bisphenol AF" -8.41 
"Ractopamine hydrochloride" -8.41 
"Dibekacin" -8.38 
"Ractopamine hydrochloride" -8.34 
"Bisphenol Z" -8.23 
 
e) 
5-HT2C agonist bound state (model 8) 
Toxicants Glide score 
(kcal/mol) 
"Xaliproden hydrochloride" -8.40 
"Xaliproden hydrochloride" -8.40 
"Naftopidil" -8.36 
"Cinacalcet hydrochloride" -8.16 
"Trifluperidol hydrochloride" -8.13 
"Fluprostenol" -8.11 
"Naftopidil" -8.11 
"6-Hydroxy-2-naphthyl disulfide" -8.10 
"Oxatomide" -8.07 
"rac Nebivolol hydrochloride" -8.05 
	 72	
f) 
5-HT2C antagonist bound state (model 11) 
Toxicants Glide score 
(kcal/mol) 
"GBR 12909 dihydrochloride" -10.38 
"GBR 12909 dihydrochloride" -10.38 
"GBR 12909 dihydrochloride" -10.32 
"GBR 12909 dihydrochloride" -10.32 
"Sertindole" -10.15 
"Sertindole" -10.15 
"Salmeterol xinafoate" -9.82 
"Salmeterol" -9.82 
"Zuclopenthixol dihydrochloride" -9.75 































SERT orthosteric binding site (PDB ID: 5I6X) 











"Indinavir sulfate" -10.54 
"Tipranavir" -10.38 
"Indinavir sulfate" -10.37 
"3-(1-{2-[(2R)-4-benzoyl-2-(3,4-difluorophenyl)morpholin-2-yl]ethyl}-4-
phenylpiperidin-4-yl)-1,1-dimethylurea hydrochloride (1:1)" 
-10.37 
"Bamifylline Hydrochloride" -10.34 
























SERT orthosteric binding site (PDB ID: 5I71) 












"Indinavir sulfate" -11.07 





phenylpiperidin-4-yl)-1,1-dimethylurea hydrochloride (1:1)" 
-10.99 
"Manidipine dihydrochloride" -10.91 

























SERT allosteric binding site (PDB ID: 5I73) 













"Daunomycin hydrochloride" -9.72 
"Bimosiamose" -9.69 
"Ketoconazole" -9.55 
"Nelfinavir mesylate" -9.51 
"Nelfinavir mesylate" -9.51 
	
